NOV 29, 2017 10:00 AM PST

WEBINAR: RAS Oncoproteins: Therapeutic Vulnerabilities

Sponsored by: Bio-Techne
Speaker
  • Associate Professor of Radiation Oncology and Pharmacology, University of North Carolina at Chapell Hill
    Biography
      Adrienne D. Cox, PhD, is Chief of the Division of Cancer Research in the Department of Radiation Oncology at the University of North Carolina at Chapel Hill (UNC-CH), Associate Professor of Pharmacology, and a member of the Lineberger Comprehensive Cancer Center (LCCC), where she directs UNC-CH's NCI-funded Cancer Cell Biology T32 Training Program. Dr. Cox serves on numerous internal and external mentoring committees and grant review panels, reviewing for the National Cancer Institute (NCI) as well as nonprofit organizations such as the American Cancer Society and the Pancreatic Cancer Action Network. She received her BA from Pomona College, her PhD from Eastern Virginia Medical School, and performed her postdoctoral studies at the La Jolla Cancer Research Foundation (now the Sanford Burnham Prebys Medical Discovery Institute). She has been involved in the study of RAS proteins since the discovery of their lipid modification by prenylation, publishing over 100 articles in peer-reviewed journals and consulting over the years for numerous pharmaceutical companies. Dr. Cox's research encompasses basic science aspects of RAS family signaling and transformation as well as translational aspects such as the development of farnesyltransferase inhibitors, originally intended to be anti-RAS therapeutics. Her laboratory is a constituent of the RAS Synthetic Lethal Network, a component of NCI's RAS Initiative that seeks to identify and target RAS therapeutic vulnerabilities.

    Abstract

    DATE: November 29, 2017
    TIME: 10:00 AM PST

    The three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins function as GDP-GTP regulated binary on-off switches that regulate diverse cytoplasmic signaling networks. In cancer and developmental disorders (RASopathies), mutationally activated RAS proteins drive aberrant signal transduction.  RAS proteins are also the founding members of a large superfamily of small GTPases comprised of >150 members.  Since their initial identification decades ago as drivers of human cancers, there has been intense interest and effort in targeting RAS for cancer treatment. RAS genes are the most frequently mutated oncogenes in the top three causes of cancer deaths in the US in 2016 (lung, colorectal and pancreatic cancers).  In this webinar, I will discuss the vulnerabilities of RAS that have been exploited for the development of pharmacologic inhibitors of RAS function.

    Learning Objectives:

    • Understand RAS function in cytoplasmic signaling
    • Understand the  potential therapeutic role of anti-RAS therapy in Cancer

    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    Loading Comments...
    Show Resources
    Attendees
    • See more